Severe Mental Illness — MCQs
On this page
A 42-year-old man with a 10-year history of paranoid schizophrenia is being assessed for community treatment order (CTO). He has had five admissions in the past 3 years, each following medication non-adherence. He lives independently and has partial insight. What is the primary legal requirement that must be met before a CTO can be established?
A 36-year-old woman with bipolar affective disorder type I has had three admissions for mania over the past 5 years despite trials of lithium, sodium valproate, and quetiapine. She is currently taking sodium valproate 1500mg daily with plasma levels in therapeutic range but continues to experience frequent hypomanic episodes every 2-3 months. She has just discovered she is 8 weeks pregnant (unplanned). Ultrasound confirms viable intrauterine pregnancy. What is the most appropriate management of her mood stabilizer?
A 25-year-old woman presents with a 3-month history of hearing multiple voices discussing her in the third person, believing her thoughts are being stolen, and that external forces control her movements. She has become socially withdrawn and her self-care has deteriorated. She has no past psychiatric history and no substance misuse. Her mother had bipolar affective disorder. Physical examination and basic investigations are normal. She is started on risperidone. According to NICE guidelines, what duration of treatment at therapeutic dose is required before considering treatment resistance if there is inadequate response?
A 40-year-old man with paranoid schizophrenia attends his depot clinic. He has been on paliperidone palmitate 100mg monthly for 6 months following multiple relapses on oral medication. He complains of restlessness, inability to sit still, and constant need to pace. He describes it as 'torture' and says he would rather stop all treatment. Examination reveals constant leg movements and hand wringing but no tremor or rigidity. What is the most appropriate management?
A 33-year-old man with bipolar affective disorder type I has been stable on lithium carbonate 1200mg daily for 4 years. He is admitted to the medical ward with suspected acute appendicitis requiring emergency laparoscopic appendicectomy. Preoperative bloods show: lithium level 0.85 mmol/L, creatinine 92 μmol/L, eGFR >90 ml/min. What is the most appropriate perioperative management of his lithium?
A 28-year-old woman with schizoaffective disorder has been maintained on amisulpride 400mg daily for 3 years. She presents with new-onset amenorrhoea for 4 months and galactorrhoea. She is sexually active and a pregnancy test is negative. Blood tests show: prolactin 3200 mU/L (normal <500 mU/L), TSH 2.4 mU/L, LH and FSH suppressed. MRI pituitary is normal. What is the most appropriate management?
A 31-year-old man with first-episode psychosis was commenced on olanzapine 10mg daily 6 weeks ago with good initial response. He now presents with increasing agitation, refuses to take medication, and believes his food is being poisoned. Mental state examination reveals thought disorder, auditory hallucinations, and persecutory delusions. He lacks capacity to consent to treatment. He lives alone and has limited family support. What is the most appropriate management approach?
A 45-year-old woman with a 20-year history of bipolar affective disorder type I presents for review. She has had 8 hospital admissions for mania and 3 for severe depression. She has tried lithium, sodium valproate, and quetiapine with poor response. She experiences mood episodes every 3-4 months. Recent thyroid function and renal function are normal. What is the most appropriate long-term pharmacological management strategy?
According to the ICD-10 diagnostic criteria, which of the following is classified as a first-rank symptom of schizophrenia?
A 37-year-old woman with bipolar affective disorder type I has been maintained on lithium carbonate 1000mg daily for 5 years with excellent mood stability. Recent routine blood tests show: lithium level 0.9 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L 6 months ago), eGFR 48 ml/min/1.73m², TSH 5.8 mU/L (normal range 0.5-4.5), free T4 12 pmol/L (normal range 9-25). She is asymptomatic. What is the most appropriate next step in management?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 21: A 42-year-old man with a 10-year history of paranoid schizophrenia is being assessed for community treatment order (CTO). He has had five admissions in the past 3 years, each following medication non-adherence. He lives independently and has partial insight. What is the primary legal requirement that must be met before a CTO can be established?
- A. The patient must be currently detained under Section 3 of the Mental Health Act (Correct Answer)
- B. The patient must have capacity to consent to the community treatment order
- C. The patient must have been detained for at least 6 months in the past year
- D. The patient must agree to accept depot antipsychotic medication
- E. Two independent psychiatrists must assess and agree on the need for CTO
Explanation: ***The patient must be currently detained under Section 3 of the Mental Health Act***- A **Community Treatment Order (CTO)** requires that the patient is currently liable to be detained for treatment under **Section 3** or other applicable sections (e.g., Section 37) of the **Mental Health Act**.- This legal framework allows for a transition from **hospital-based detention** to supervised treatment in the community, retaining the power of **recall** if conditions are not met.*The patient must have capacity to consent to the community treatment order*- **Capacity** is not a legal prerequisite for the implementation of a CTO under the **Mental Health Act**.- A CTO can be applied even if a patient lacks the **mental capacity** to consent, provided it is necessary for their health, safety, or the protection of others.*The patient must have been detained for at least 6 months in the past year*- There is no specific legal requirement regarding the **minimum duration** of prior hospital detention (e.g., 6 months) to qualify for a CTO.- The decision is based on the **history of relapse** and the need for ongoing supervision rather than a fixed number of months spent as an inpatient.*The patient must agree to accept depot antipsychotic medication*- While **medication adherence** is often a condition of a CTO, the patient’s agreement to a specific formulation like **depot medication** is not a primary legal requirement for its establishment.- If a patient refuses treatment under a CTO, they may be **recalled to the hospital**, where they can be treated under the original detention powers.*Two independent psychiatrists must assess and agree on the need for CTO*- The legal requirement for establishing a CTO involves the agreement between the **Responsible Clinician (RC)** and an **Approved Mental Health Professional (AMHP)**.- It does not specifically mandate **two independent psychiatrists** to assess and agree, as the AMHP provides an independent perspective.
Question 22: A 36-year-old woman with bipolar affective disorder type I has had three admissions for mania over the past 5 years despite trials of lithium, sodium valproate, and quetiapine. She is currently taking sodium valproate 1500mg daily with plasma levels in therapeutic range but continues to experience frequent hypomanic episodes every 2-3 months. She has just discovered she is 8 weeks pregnant (unplanned). Ultrasound confirms viable intrauterine pregnancy. What is the most appropriate management of her mood stabilizer?
- A. Continue sodium valproate at current dose as risks of relapse outweigh teratogenic risks
- B. Stop sodium valproate immediately and do not start alternative medication during pregnancy
- C. Continue sodium valproate but add high-dose folic acid supplementation
- D. Stop sodium valproate and switch to lithium with close monitoring (Correct Answer)
- E. Stop sodium valproate and switch to lamotrigine with rapid titration
Explanation: ***Stop sodium valproate and switch to lithium with close monitoring*** - **Sodium valproate** is highly teratogenic, causing a 10% risk of major malformations and a 30-40% risk of **neurodevelopmental delay**; it must be stopped immediately in pregnancy. - **Lithium** is the preferred choice for severe, treatment-resistant bipolar disorder in pregnancy, as its risk of **Ebstein’s anomaly** (0.1%) is significantly lower than the risks associated with valproate. *Continue sodium valproate at current dose as risks of relapse outweigh teratogenic risks* - Regulatory bodies (like the MHRA/NICE) state that valproate should **not be used** in pregnancy for bipolar disorder due to its extreme risk profile. - The risks of **fetal valproate syndrome** and cognitive impairment far outweigh the potential benefits of continuing the medication in this scenario. *Stop sodium valproate immediately and do not start alternative medication during pregnancy* - This patient has **Bipolar Type I** with a history of three hospitalizations, making the risk of a severe **manic relapse** during pregnancy extremely high if untreated. - Relapse poses significant dangers, including **suicidality**, poor prenatal care, and potential harm to the fetus from maternal behavior. *Continue sodium valproate but add high-dose folic acid supplementation* - While **5mg folic acid** is recommended for women on antiepileptics, it does not mitigate the significant **neurodevelopmental risks** or many physical malformations caused by valproate. - Continuing valproate in a pregnant woman with bipolar disorder is considered **contraindicated** if alternative treatments like lithium are available. *Stop sodium valproate and switch to lamotrigine with rapid titration* - **Lamotrigine** requires a very slow titration over weeks to avoid **Stevens-Johnson Syndrome**, leaving the patient unprotected during a high-risk period. - Although it has a good safety profile, lamotrigine is primarily effective for the **depressive pole** and may not be robust enough to manage her recurring hypomania and severe mania history.
Question 23: A 25-year-old woman presents with a 3-month history of hearing multiple voices discussing her in the third person, believing her thoughts are being stolen, and that external forces control her movements. She has become socially withdrawn and her self-care has deteriorated. She has no past psychiatric history and no substance misuse. Her mother had bipolar affective disorder. Physical examination and basic investigations are normal. She is started on risperidone. According to NICE guidelines, what duration of treatment at therapeutic dose is required before considering treatment resistance if there is inadequate response?
- A. 2 weeks of treatment at adequate therapeutic dose
- B. 4 weeks of treatment at adequate therapeutic dose
- C. 4-6 weeks of treatment at adequate therapeutic dose (Correct Answer)
- D. 8 weeks of treatment at adequate therapeutic dose
- E. 12 weeks of treatment at adequate therapeutic dose
Explanation: ***4-6 weeks of treatment at adequate therapeutic dose***- According to **NICE guidelines** for schizophrenia, an adequate trial of an antipsychotic medication requires treatment at an optimal dose for a period of **4 to 6 weeks**.- This duration is necessary to assess clinical efficacy; if the response is inadequate after this window, the medication is considered **ineffective** and a switch is indicated.*2 weeks of treatment at adequate therapeutic dose*- This duration is too short for a definitive trial, as many patients show significant **symptom reduction** only after the first 14 days of therapeutic dosing.- Declaring failure at this stage risks premature discontinuation of a medication that may have been **clinically effective** with more time.*4 weeks of treatment at adequate therapeutic dose*- While some guidelines mention 4 weeks, **NICE specifically specifies a range** of 4-6 weeks to allow for individual variation in pharmacodynamics.- Assessment at 4 weeks alone might miss the **delayed therapeutic benefit** often seen in patients with severe psychosis.*8 weeks of treatment at adequate therapeutic dose*- Waiting 8 weeks exceeds the standard recommended timeframe for assessing initial drug response in **first-episode psychosis**.- Prolonged trials of ineffective medication unnecessarily extend the **duration of untreated psychosis**, which is associated with poorer long-term outcomes.*12 weeks of treatment at adequate therapeutic dose*- A 12-week trial is far beyond the **4-6 week benchmark** used to define treatment failure or move toward a diagnosis of **treatment-resistant schizophrenia**.- At this point, the patient should have already been evaluated for **clozapine eligibility** if two previous sequential trials of 4-6 weeks had failed.
Question 24: A 40-year-old man with paranoid schizophrenia attends his depot clinic. He has been on paliperidone palmitate 100mg monthly for 6 months following multiple relapses on oral medication. He complains of restlessness, inability to sit still, and constant need to pace. He describes it as 'torture' and says he would rather stop all treatment. Examination reveals constant leg movements and hand wringing but no tremor or rigidity. What is the most appropriate management?
- A. Add procyclidine 5mg three times daily to manage extrapyramidal side effects
- B. Reduce paliperidone palmitate dose to 75mg monthly and review in 4 weeks
- C. Add propranolol 30mg three times daily to manage akathisia symptoms (Correct Answer)
- D. Switch from paliperidone palmitate to clozapine for treatment-resistant schizophrenia
- E. Continue current treatment and reassure that symptoms will improve with time
Explanation: ***Add propranolol 30mg three times daily to manage akathisia symptoms*** - The patient's symptoms of subjective **restlessness**, inability to sit still, constant need to pace, and objective **constant leg movements** and hand wringing are classic for **akathisia**, a distressing **extrapyramidal side effect (EPS)** of antipsychotics. - **Propranolol**, a **lipophilic beta-blocker**, is the **first-line pharmacological treatment** for akathisia, offering effective relief by acting on central serotonin receptors. *Add procyclidine 5mg three times daily to manage extrapyramidal side effects* - **Procyclidine** is an **anticholinergic medication** primarily used to treat **parkinsonism** (e.g., tremor, rigidity) or **acute dystonia**, not typically effective for **akathisia**. - Anticholinergics can cause significant side effects like **blurred vision**, dry mouth, constipation, and cognitive impairment, and are generally less effective for akathisia. *Reduce paliperidone palmitate dose to 75mg monthly and review in 4 weeks* - While dose reduction can alleviate EPS, this patient has a history of **multiple relapses** on oral medication, making dose reduction a high risk for **psychotic recurrence** and potential destabilization. - Due to the **long half-life** of paliperidone palmitate depot, a dose reduction would not provide immediate symptomatic relief for his severe distress, which is crucial for adherence. *Switch from paliperidone palmitate to clozapine for treatment-resistant schizophrenia* - **Clozapine** is indicated for **treatment-resistant schizophrenia**, defined as failure of at least two adequate trials of different antipsychotics, which is not clearly established here as the issue is a manageable side effect. - Switching to clozapine involves significant risks, including the need for intensive **hematological monitoring** due to agranulocytosis risk, and would be premature before addressing the akathisia directly. *Continue current treatment and reassure that symptoms will improve with time* - Akathisia is profoundly distressing (described as "torture") and is a major cause of **treatment non-adherence** and can increase the **risk of suicide** or violence. - Reassurance alone is insufficient and inappropriate given the severity of his symptoms and the need for prompt, effective **active management** to alleviate his distress and maintain treatment adherence.
Question 25: A 33-year-old man with bipolar affective disorder type I has been stable on lithium carbonate 1200mg daily for 4 years. He is admitted to the medical ward with suspected acute appendicitis requiring emergency laparoscopic appendicectomy. Preoperative bloods show: lithium level 0.85 mmol/L, creatinine 92 μmol/L, eGFR >90 ml/min. What is the most appropriate perioperative management of his lithium?
- A. Continue lithium throughout the perioperative period with daily level monitoring
- B. Omit lithium on the day of surgery and restart when oral intake resumes (Correct Answer)
- C. Stop lithium 48 hours preoperatively and restart 24 hours postoperatively
- D. Stop lithium 24 hours preoperatively and restart when renal function is confirmed stable
- E. Continue lithium but reduce dose by 50% on day of surgery
Explanation: ***Omit lithium on the day of surgery and restart when oral intake resumes*** - For emergency or minor surgery, **omitting lithium** on the day of the procedure is sufficient to minimize the risk of **toxicity** caused by fluid shifts and dehydration. - It should be restarted as soon as the patient is **fluid-stable** and oral intake is resumed to prevent the risk of a **bipolar relapse**. *Continue lithium throughout the perioperative period with daily level monitoring* - This approach is dangerous because **general anesthesia** and intraoperative **fluid loss** can cause rapid fluctuations in serum levels, leading to **neurotoxicity**. - Lithium also interacts with **neuromuscular blocking agents**, potentially prolonging their effects during surgery. *Stop lithium 48 hours preoperatively and restart 24 hours postoperatively* - This protocol is typically reserved for **major surgeries** involving significant fluid shifts, such as cardiac or major abdominal surgery, which does not apply to this laparoscopy. - Prolonged cessation of lithium, especially without a gradual taper, is associated with a high rate of **rapid relapse** in bipolar I patients. *Stop lithium 24 hours preoperatively and restart when renal function is confirmed stable* - While cautious regarding **renal clearance**, a 24-hour cessation is often unnecessary for stable patients undergoing procedures where they can quickly resume **oral intake**. - Extended cessation increases the time the patient is without therapeutic coverage, raising the risk of **acute mood episodes**. *Continue lithium but reduce dose by 50% on day of surgery* - **Dose reduction** is not a standard perioperative practice; it makes levels unpredictable and does not protect against the risk of **acute kidney injury** during surgery. - The narrow **therapeutic index** of lithium makes a fixed-percentage reduction unsafe compared to simply omitting a single dose.
Question 26: A 28-year-old woman with schizoaffective disorder has been maintained on amisulpride 400mg daily for 3 years. She presents with new-onset amenorrhoea for 4 months and galactorrhoea. She is sexually active and a pregnancy test is negative. Blood tests show: prolactin 3200 mU/L (normal <500 mU/L), TSH 2.4 mU/L, LH and FSH suppressed. MRI pituitary is normal. What is the most appropriate management?
- A. Continue amisulpride and add cabergoline to lower prolactin levels
- B. Switch amisulpride to quetiapine which has lower risk of hyperprolactinaemia
- C. Reduce amisulpride dose to 200mg daily and monitor prolactin levels
- D. Continue amisulpride and reassure that hyperprolactinaemia is benign
- E. Switch amisulpride to aripiprazole which may reduce prolactin levels (Correct Answer)
Explanation: ***Switch amisulpride to aripiprazole which may reduce prolactin levels*** - **Amisulpride** is a potent **D2 antagonist** leading to high prolactin, while **aripiprazole** is a **partial dopamine agonist** known to reduce elevated prolactin levels. - Switching to an antipsychotic like **aripiprazole** with a different mechanism is the most appropriate management for drug-induced hyperprolactinaemia. *Continue amisulpride and add cabergoline to lower prolactin levels* - Adding **cabergoline**, a **dopamine agonist**, to an antipsychotic (dopamine antagonist) can counteract its therapeutic effects and **exacerbate psychotic symptoms**. - It is generally not advisable to treat antipsychotic-induced side effects with another drug that may interfere with the primary psychiatric treatment. *Switch amisulpride to quetiapine which has lower risk of hyperprolactinaemia* - While **quetiapine** is **prolactin-sparing**, **aripiprazole** is often preferred because its unique **partial agonism** can actively *reduce* already elevated prolactin levels, rather than just preventing further increases. - Aripiprazole's mechanism offers a more direct and effective approach for resolving existing hyperprolactinaemia symptoms. *Reduce amisulpride dose to 200mg daily and monitor prolactin levels* - Reducing the dose of **amisulpride** may not be sufficient to normalize prolactin levels due to its high affinity for pituitary dopamine receptors. - Dose reduction carries a significant risk of **psychiatric relapse** for a patient previously stable on a higher dose, without guaranteeing resolution of **amenorrhoea** or **galactorrhoea**. *Continue amisulpride and reassure that hyperprolactinaemia is benign* - Long-term **hyperprolactinaemia** is not benign; it can lead to **hypogonadism**, **reduced bone mineral density** (osteoporosis), and sexual dysfunction. - Symptomatic cases with **amenorrhoea** and **galactorrhoea** require intervention to protect the patient's long-term physical health and quality of life.
Question 27: A 31-year-old man with first-episode psychosis was commenced on olanzapine 10mg daily 6 weeks ago with good initial response. He now presents with increasing agitation, refuses to take medication, and believes his food is being poisoned. Mental state examination reveals thought disorder, auditory hallucinations, and persecutory delusions. He lacks capacity to consent to treatment. He lives alone and has limited family support. What is the most appropriate management approach?
- A. Arrange urgent assessment for admission under Mental Health Act and commence depot antipsychotic (Correct Answer)
- B. Increase oral olanzapine to 20mg daily and arrange daily supervised administration
- C. Initiate community treatment order to ensure medication compliance
- D. Arrange crisis team intensive home treatment as alternative to admission
- E. Administer intramuscular olanzapine and observe response before deciding on admission
Explanation: ***Arrange urgent assessment for admission under Mental Health Act and commence depot antipsychotic*** - The patient is experiencing an **acute psychotic relapse** with severe symptoms, **lacks capacity** to make treatment decisions, and **refuses oral medication** due to paranoia, necessitating **involuntary admission** under the **Mental Health Act** to ensure safety and initiate treatment. - Given the clear history of **medication non-adherence** leading to relapse (believing food/meds are poisoned), initiating a **long-acting injectable (depot) antipsychotic** is the most appropriate strategy to improve adherence and prevent future relapses once stabilized. *Increase oral olanzapine to 20mg daily and arrange daily supervised administration* - This approach is unsuitable because the patient is **actively refusing** oral medication, believing it is **poisoned**, making daily supervised administration impractical and likely ineffective. - Increasing the dose of a medication the patient won't take does not address the core issue of **non-adherence** and his current **lack of capacity** to engage with treatment. *Initiate community treatment order to ensure medication compliance* - A **Community Treatment Order (CTO)** is typically implemented for patients who have been **detained** under the Mental Health Act and are being discharged from hospital, to ensure compliance in the community. It is not for *initiating* treatment in an acutely unwell patient who requires admission. - The patient's current severe symptoms, **lack of capacity**, and **refusal of treatment** in the community make him unsuitable for a CTO at this stage; he first requires inpatient stabilization. *Arrange crisis team intensive home treatment as alternative to admission* - **Intensive home treatment** requires a degree of **patient cooperation** and engagement, which is absent here due to his severe **psychotic symptoms**, **agitation**, and **refusal of care**. - Furthermore, the patient **lives alone** and has **limited family support**, making home treatment challenging and potentially unsafe given the severity of his **persecutory delusions** and risk of harm to self or others. *Administer intramuscular olanzapine and observe response before deciding on admission* - While **intramuscular olanzapine** can be used for **acute agitation** and symptom control, it is a **short-term measure** and does not address the need for a comprehensive, ongoing treatment plan for a patient with **acute relapse** and **lack of capacity**. - Given the severity of his symptoms, **lack of capacity**, and **poor support**, admission is strongly indicated for **safety**, thorough assessment, and initiation of effective long-term treatment, regardless of the immediate response to a single IM dose.
Question 28: A 45-year-old woman with a 20-year history of bipolar affective disorder type I presents for review. She has had 8 hospital admissions for mania and 3 for severe depression. She has tried lithium, sodium valproate, and quetiapine with poor response. She experiences mood episodes every 3-4 months. Recent thyroid function and renal function are normal. What is the most appropriate long-term pharmacological management strategy?
- A. High-dose quetiapine monotherapy up to 800mg daily
- B. Lithium and sodium valproate combination therapy (Correct Answer)
- C. Lamotrigine monotherapy with gradual titration to therapeutic dose
- D. Depot antipsychotic with mood stabilizer augmentation
- E. Carbamazepine monotherapy as alternative mood stabilizer
Explanation: ***Lithium and sodium valproate combination therapy*** - This patient exhibits **treatment-resistant rapid-cycling bipolar disorder** (defined as ≥4 episodes per year), having failed trials of lithium, valproate, and quetiapine monotherapy. - **NICE guidelines** recommend combination therapy with two mood stabilizers, like **lithium and sodium valproate**, specifically for patients who do not respond to monotherapy and have a high frequency of relapse. *High-dose quetiapine monotherapy up to 800mg daily* - While **quetiapine** is effective in both mania and depression, this patient has already failed quetiapine trials, making further monotherapy unlikely to succeed. - Higher doses increase the risk of **metabolic side effects** and sedation without guaranteeing better mood stabilization in **rapid-cycling** cases. *Lamotrigine monotherapy with gradual titration to therapeutic dose* - **Lamotrigine** is primarily effective for preventing **bipolar depression** but has significantly less efficacy in preventing or treating **manic episodes**. - Given the patient's history of 8 manic admissions, lamotrigine monotherapy would not provide sufficient protection against further **mania**. *Depot antipsychotic with mood stabilizer augmentation* - **Depot antipsychotics** are generally reserved for patients with poor **medication adherence**, which is not the primary issue identified here. - While augmentation is useful, the combination of two gold-standard **mood stabilizers** is preferred over depot therapy for complex maintenance in **treatment-resistant** patients. *Carbamazepine monotherapy as alternative mood stabilizer* - **Carbamazepine** is generally considered a second-line mood stabilizer due to its **enzyme-induction** properties and multiple drug-drug interactions. - It has a weaker evidence base compared to lithium and valproate for long-term **prophylaxis** in severe, refractory bipolar type I.
Question 29: According to the ICD-10 diagnostic criteria, which of the following is classified as a first-rank symptom of schizophrenia?
- A. Persistent delusions that are culturally inappropriate and completely impossible
- B. Thought echo, thought insertion, thought withdrawal, or thought broadcasting (Correct Answer)
- C. Persistent hallucinations in any modality occurring daily for at least one month
- D. Breaks or interpolations in the train of thought resulting in incoherence
- E. Marked apathy, paucity of speech, and blunting of emotional responses
Explanation: ***Thought echo, thought insertion, thought withdrawal, or thought broadcasting*** - These are classic **Schneiderian first-rank symptoms**, representing a disturbance in the **boundary of the self** or **thought possession**, crucial for schizophrenia diagnosis in ICD-10. - **ICD-10** specifies that the presence of at least one of these clear-cut symptoms of **thought alienation** for a period of one month or more is sufficient for diagnosis. *Persistent delusions that are culturally inappropriate and completely impossible* - While these are descriptive of **bizarre delusions**, a significant feature of schizophrenia, they are considered a broader category of delusion rather than a specific **first-rank symptom** itself. - **Schneider's first-rank symptoms** focus on very specific types of delusions, such as **delusional perception**, rather than general bizarre content. *Persistent hallucinations in any modality occurring daily for at least one month* - For hallucinations to be classified as first-rank, they must be highly specific, such as **auditory hallucinations** in the form of voices giving a **running commentary** or **discussing the patient** in the third person, or **thought echo**. - General persistent hallucinations in *any modality* (e.g., visual, tactile) are characteristic of schizophrenia but do not meet the strict criteria for **first-rank symptoms**. *Breaks or interpolations in the train of thought resulting in incoherence* - This describes **formal thought disorder** or **loosening of associations**, which is a core feature of the **disorganization syndrome** in schizophrenia. - Although a major diagnostic criterion for schizophrenia in ICD-10, formal thought disorder is not categorized as one of the specific **Schneiderian first-rank symptoms**. *Marked apathy, paucity of speech, and blunting of emotional responses* - These are quintessential **negative symptoms** of schizophrenia, reflecting a reduction or absence of normal mental functions and behaviors. - While critical for diagnosis and indicating significant impairment, **negative symptoms** are distinct from the specific **first-rank symptoms** defined by Schneider and utilized in ICD-10.
Question 30: A 37-year-old woman with bipolar affective disorder type I has been maintained on lithium carbonate 1000mg daily for 5 years with excellent mood stability. Recent routine blood tests show: lithium level 0.9 mmol/L, creatinine 145 μmol/L (baseline 85 μmol/L 6 months ago), eGFR 48 ml/min/1.73m², TSH 5.8 mU/L (normal range 0.5-4.5), free T4 12 pmol/L (normal range 9-25). She is asymptomatic. What is the most appropriate next step in management?
- A. Stop lithium immediately and switch to sodium valproate due to renal impairment
- B. Continue lithium but reduce dose and increase monitoring frequency of renal function (Correct Answer)
- C. Continue lithium at current dose as levels are therapeutic and side effects are acceptable
- D. Stop lithium and switch to lamotrigine as first-line alternative for mood stabilization
- E. Add amiloride to lithium therapy to reduce polyuria and protect renal function
Explanation: ***Continue lithium but reduce dose and increase monitoring frequency of renal function*** - The patient exhibits **declining renal function** (eGFR 48 ml/min, CKD stage 3a) and **subclinical hypothyroidism** (TSH 5.8 mU/L), which are common long-term side effects of lithium that require dose adjustment and closer surveillance. - Given the **excellent mood stability**, the preferred approach is to reduce the lithium dose to target a lower therapeutic level (0.6–0.8 mmol/L) and increase monitoring of renal function, typically every 3 months, before considering discontinuation. *Stop lithium immediately and switch to sodium valproate due to renal impairment* - **Abrupt discontinuation** of lithium is associated with a very high risk of relapse (up to 50% within a year) in stable bipolar I patients. - Lithium is not strictly contraindicated until **eGFR falls below 30 ml/min**, so an immediate switch is not yet mandatory at CKD stage 3a. *Continue lithium at current dose as levels are therapeutic and side effects are acceptable* - A **rising creatinine** (from 85 to 145 μmol/L) and an eGFR below 60 ml/min indicate significant **nephrotoxicity** that cannot be ignored. - Maintaining the same dose increases the risk of **lithium toxicity**, as lithium is primarily excreted by the kidneys and its clearance decreases with renal impairment. *Stop lithium and switch to lamotrigine as first-line alternative for mood stabilization* - While **lamotrigine** is effective for bipolar depression, it is generally less effective than lithium or valproate for preventing **manic relapses** in bipolar type I disorder. - Switching is a complex process and should only be initiated if dose reduction fails to stabilize the **eGFR decline** or if the patient becomes symptomatic. *Add amiloride to lithium therapy to reduce polyuria and protect renal function* - **Amiloride** is specifically used to treat **nephrogenic diabetes insipidus** by blocking lithium entry into the epithelial sodium channels of the collecting duct, but the patient is asymptomatic for polyuria. - It does not directly improve the **glomerular filtration rate (eGFR)** or treat the interstitial fibrosis associated with long-term lithium use.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free